GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom

What happened

Gilead Sciences reported Q3 2026 revenue of $8.3 billion, up 6.8% year on year and above analyst estimates. It raised full-year revenue guidance to $31.15 billion at the midpoint but lowered adjusted earnings per share guidance to -$1.03 at the midpoint.

Confirmed

Global impact / market context

The mixed guidance matters because higher revenue guidance signals stronger expected sales, especially from HIV treatments, while the lowered profit guidance points to rising costs or pressure on profit per sale. That combination can change how investors judge future earnings and stock value.

Analyst inference

Gilead's results show HIV treatments driving growth, with demand for BIKTARVY, DESCOVY and injectable Yeztugo supporting sales. At the same time, operating margin fell to 41.7% from 42.8%, and policy headwinds are flagged, which means rules or government actions could affect future revenue or costs.

Analyst inference

What to watch

1. Watch whether full-year revenue reaches the raised $31.15 billion midpoint guidance and whether adjusted earnings per share matches the lowered -$1.03 midpoint guidance. Confirmed
2. Track HIV treatment sales, especially BIKTARVY, DESCOVY and Yeztugo, because continued demand for these products is the stated driver of Gilead's revenue growth. Analyst inference
3. Monitor how looming policy headwinds develop, since new rules or government actions could raise costs, pressure prices, or reduce revenue from Gilead's treatments. Proposed

Evidence

• stockstory.org